Form 4: Alector Director Richard Scheller Receives Significant Equity Grants

Alector, Inc. Director Richard H. Scheller was granted 28,700 restricted stock units and 9,450 stock options, aligning his interests with shareholders.

Summary

• Richard H. Scheller, a Director of Alector, Inc. (ALEC), reported the acquisition of equity securities on June 11, 2025.
• The transaction involved the acquisition of 28,700 shares of Common Stock in the form of Restricted Stock Units (RSUs) at a price of $0.00 per share.
• These RSUs are set to vest on the earlier of June 11, 2026, or the date of Alector's next annual meeting of stockholders.
• Following this transaction, Mr. Scheller beneficially owns 95,366 shares of Common Stock.
• Additionally, Mr. Scheller acquired 9,450 stock options with an exercise price of $1.63 per share.
• These stock options vest in 12 equal monthly installments beginning on July 11, 2025, or earlier on the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.
• The stock options have an expiration date of June 10, 2035.
• After this transaction, Mr. Scheller beneficially owns 9,450 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive for aligning interests but not a significant market-moving event. It reflects standard corporate governance practices.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance and value creation.
• Equity compensation is a standard practice for attracting and retaining experienced board members in the biotechnology sector.

Future Outlook

The vesting schedules for both the restricted stock units and stock options extend into the future, indicating a long-term incentive structure for the director. The RSUs vest by June 11, 2026, or the next annual meeting, and options vest monthly starting July 2025, or earlier based on the one-year anniversary or next annual meeting.

Industry Context

Equity grants, such as restricted stock units and stock options, are a common form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of board members with the long-term performance of the company, which is particularly relevant in a sector characterized by long development cycles and significant R&D investments.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a standard practice across the biotechnology and pharmaceutical industries, comparable to compensation structures at companies like Biogen Inc. or Amgen Inc., which frequently utilize equity to incentivize leadership.
• The vesting schedules, tied to future dates or corporate events like annual meetings, are typical for ensuring continued commitment and performance from board members, mirroring practices seen in many publicly traded life sciences companies.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with shareholder value creation, potentially leading to more focused long-term strategic decisions.
• Employees: While not directly impacting general employees, such compensation practices for leadership can set a precedent for performance-based incentives within the company.

Next Steps

• Vesting of 28,700 restricted stock units on the earlier of June 11, 2026, or the date of the Issuer's next annual meeting of stockholders.
• Monthly vesting of 9,450 stock options beginning July 11, 2025, or earlier on the one-year anniversary of the grant date or the date of the Issuer's next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Alector, ALEC, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Biotechnology, Pharmaceuticals